Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND StudyMay 25th 2023
Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
IO Therapy in mCRPC and Clinical PearlsMay 24th 2023
Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.
Practical Application of PARP Inhibitors in Metastatic CRPCMay 24th 2023
Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.
Birtamimab Under Investigation in Mayo Stage IV AL AmyloidosisMay 19th 2023
Morie A. Gertz, MD, discusses the limitations of the current Mayo Stage IV amyloidosis treatment landscape, the rationale for investigating birtamimab in this population, and the importance of raising awareness for the AFFIRM-AL trial.
Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL AmyloidosisMay 17th 2023
Morie A. Gertz, MD, discusses the rationale for the phase 3 AFFIRM-AL trial in patients with amyloid light chain amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.
Genomic Testing Is Critical for Improved Personalized Medicine and Treatment Sequencing in Breast CancerMay 17th 2023
Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer.
Overview of the Metastatic Castration-Resistant Prostate Cancer Treatment ParadigmMay 17th 2023
Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).
Ibrutinib-Containing Regimens Remain of Interest Despite Agent’s Withdrawal in MCL and MZLMay 16th 2023
Thomas M. Habermann, MD, expands on previous data that supported the initial accelerated approval of ibrutinib in marginal zone lymphoma and mantle cell lymphoma, phase 3 data leading to the agent’s voluntary withdrawal, and investigations of ibrutinib and other BTK inhibitors that could significantly change the treatment landscape in mantle cell lymphoma and marginal zone lymphoma.
Novel Treatment Modalities in Metastatic Hormone-Sensitive Prostate CancerMay 10th 2023
Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.
Educating Patients on Treatment Options in Metastatic HSPCMay 10th 2023
Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.
Emerging Data Help Steer CDK4/6 Inhibitor Choice in HR+/HER2– Breast Cancer
Karen S. Anderson, MD, PhD, discusses emerging data and role for CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer, along with the growing use of antibody-drug conjugates across the breast cancer spectrum and updates in triple-negative breast cancer.
Audience Q&A: Best Practices in Managing HER2-Amplified CRCMay 5th 2023
Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
Metastatic Hormone-Sensitive Prostate Cancer: Data from TITAN and PEACE-1May 3rd 2023
Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.
Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHESMay 3rd 2023
Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.
Evolutions in the HER2-Amplified CRC Treatment LandscapeApril 28th 2023
Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.
Factors in Selecting Therapy for Patients With Metastatic Hormone-Sensitive Prostate CancerApril 19th 2023
A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.
Treatment Goals for Patients With Metastatic Hormone-Sensitive Prostate CancerApril 19th 2023
Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.
Desai Discusses the Significance of a Supportive, Foundational Fellowship ExperienceApril 17th 2023
Dr Desai discusses the aspects of his oncology fellowship experience that have had the greatest influence on his career growth, the role of mentorship throughout his fellowship and transition to a full-time faculty position, and his advice for current and future oncology fellows.